. V D	1		14,	
$\Delta \nu_{}$				

Award Number: DAMD17-01-1-0128

TITLE: Metabolizing Enzyme Polymorphisms and Prognosis Among

Women Treated for Breast Cancer

PRINCIPAL INVESTIGATOR: Carol Sweeney, Ph.D.

CONTRACTING ORGANIZATION: University of Minnesota

Minneapolis, Minnesota 55455-2070

REPORT DATE: October 2002

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030313 151

REPORT DOCUMENTATION PAGE

Form Approved

REPORT DOCUMENTATION PAGE

OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE	3. REPORT TYPE AND	DATES COVERE	D
	October 2002	Annual (28 Sep		
4. TITLE AND SUBTITLE			5. FUNDING N	
Metabolizing Enzyme Poly	sis Among	DAMD17-01		
Women Treated for Breast	_	- -		
6. AUTHOR(S)				
Carol Sweeney, Ph.D.		· ·		
	. 0			
7 DEDECORNING ODCANIZATION	ME(S) AND ADDRESS(ES)		8 DEDECTION	IG ORGANIZATION
7. PERFORMING ORGANIZATION NAM University of Minnesota	WEIS! AND ADDRESS(ES)		8. PERFORMIN REPORT NU	
University of Minnesota Minneapolis, Minnesota 55455-207	70		On I NU	
	7			
E-Mail: sweeney@epi.umn.edu				
		: 1		
9. SPONSORING / MONITORING AGE	NCY NAME(S) AND ADDRESSIES	3)	10. SPONSORI	ING / MONITORING
				REPORT NUMBER
U.S. Army Medical Research and M				
Fort Detrick, Maryland 21702-501				
		Ć v.		
			<u> </u>	
11. SUPPLEMENTARY NOTES				H _{and}
	1			0.0
		•		
12a. DISTRIBUTION / AVAILABILITY S	STATEMENT			12b. DISTRIBUTION CODE
Approved for Public Rele		limited		DISTRIBUTION CODE
TOT TOT TOTIC VETE	ULLULLEDGE OIL OIL			
		•		
er stad of the second of the s		•		1000
13. ABSTRACT (Maximum 200 Words	's <i>)</i>			1
IVIANI IVIANIIIIIII ZUU VVOIG			./ .	
m1- 4			_	
This study will use arch	nived tissue and data	co examine surv	ival of wo	men treated for
breast cancer in relation	on to inherited polym	orphisms of drug	metaboliz	ing enzymes. During
breast cancer in relation the first year of fundir	on to inherited polym ng, we have completed	orphisms of drug compilation of	metaboliz tumor regi	ing enzymes. During
breast cancer in relation the first year of fundir eligible subjects (Task	on to inherited polyming, we have completed 1 of the approved st	orphisms of drug compilation of atement of work)	metaboliz tumor regi . We have	zing enzymes. During stry data for also completed
breast cancer in relation the first year of funding eligible subjects (Task study start-up tasks, in	on to inherited polyming, we have completed 1 of the approved standard IRB review,	orphisms of drug compilation of atement of work) hiring study sta	metaboliz tumor regi . We have .ff, creati	zing enzymes. During stry data for also completed ng data collection
breast cancer in relation the first year of funding eligible subjects (Task study start-up tasks, in forms, establishing a st	on to inherited polyming, we have completed 1 of the approved structuring IRB review, tudy database, and tra	orphisms of drug compilation of atement of work) hiring study sta aining study sta	metaboliz tumor regi . We have aff, creati aff on data	zing enzymes. During stry data for also completed ng data collection collection
breast cancer in relation the first year of funding eligible subjects (Task study start-up tasks, in forms, establishing a start-up tasks).	on to inherited polyming, we have completed 1 of the approved structuring IRB review, tudy database, and tructuring transfer (Tessue samples (Tessue samples)	orphisms of drug compilation of atement of work) hiring study sta aining study sta ask 2 of the app	metaboliz tumor regi . We have aff, creati aff on data proved stat	zing enzymes. During stry data for also completed ing data collection collection ement of work) has
breast cancer in relation the first year of funding eligible subjects (Task study start-up tasks, in forms, establishing a st procedures. Collection begun. Activities curre	on to inherited polyming, we have completed 1 of the approved structuring IRB review, tudy database, and tructuring transfer (Tently in progress inc	orphisms of drug compilation of atement of work) hiring study sta aining study sta ask 2 of the app lude obtaining p	metaboliz tumor regi . We have aff, creati aff on data proved state pathology s	zing enzymes. During stry data for also completed on collection collection ement of work) has alides and blocks,
breast cancer in relation the first year of funding eligible subjects (Task study start-up tasks, in forms, establishing a st procedures. Collection begun. Activities current review of slides by the	on to inherited polyming, we have completed 1 of the approved structuding IRB review, tudy database, and tructudy in progress incompleted study pathologist, as	orphisms of drug compilation of atement of work) hiring study sta aining study sta ask 2 of the app lude obtaining p nd abstracting i	metaboliz tumor regi . We have aff, creati aff on data proved state athology s anformation	zing enzymes. During stry data for e also completed on collection collection ement of work) has slides and blocks, a from pathology
breast cancer in relation the first year of fundir eligible subjects (Task study start-up tasks, in forms, establishing a st procedures. Collection begun. Activities currective of slides by the reports into the study of	on to inherited polyming, we have completed 1 of the approved standing IRB review, tudy database, and transfer in progress inceptly in progress inceptly pathologist, and database. As describe	orphisms of drug compilation of atement of work) hiring study sta aining study sta ask 2 of the app lude obtaining p nd abstracting i ed in the statem	metaboliz tumor regi . We have aff, creati aff on data proved state athology s anformation ment of wor	sing enzymes. During stry data for also completed on a collection a collection dement of work) has alides and blocks, a from pathology of the data collection
breast cancer in relation the first year of fundir eligible subjects (Task study start-up tasks, in forms, establishing a st procedures. Collection begun. Activities currective of slides by the reports into the study of tasks will continue into	on to inherited polyming, we have completed 1 of the approved standing IRB review, tudy database, and transfer in progress inceptly in progress inceptly pathologist, and database. As describe	orphisms of drug compilation of atement of work) hiring study sta aining study sta ask 2 of the app lude obtaining p nd abstracting i ed in the statem	metaboliz tumor regi . We have aff, creati aff on data proved state athology s anformation ment of wor	sing enzymes. During stry data for also completed on a collection a collection dement of work) has alides and blocks, a from pathology of the data collection
breast cancer in relation the first year of funding eligible subjects (Task study start-up tasks, in forms, establishing a st procedures. Collection begun. Activities currently review of slides by the reports into the study of	on to inherited polyming, we have completed 1 of the approved standing IRB review, tudy database, and transfer in progress inceptly in progress inceptly pathologist, and database. As describe	orphisms of drug compilation of atement of work) hiring study sta aining study sta ask 2 of the app lude obtaining p nd abstracting i ed in the statem	metaboliz tumor regi . We have aff, creati aff on data proved state athology s anformation ment of wor	sing enzymes. During stry data for also completed on a collection a collection dement of work) has alides and blocks, a from pathology of the data collection
breast cancer in relation the first year of funding eligible subjects (Task study start-up tasks, in forms, establishing a st procedures. Collection begun. Activities current review of slides by the reports into the study of tasks will continue into	on to inherited polyming, we have completed 1 of the approved standing IRB review, tudy database, and transfer in progress inceptly in progress inceptly pathologist, and database. As describe	orphisms of drug compilation of atement of work) hiring study sta aining study sta ask 2 of the app lude obtaining p nd abstracting i ed in the statem	metaboliz tumor regi . We have aff, creati aff on data proved state athology s anformation ment of wor	sing enzymes. During stry data for also completed on a collection a collection dement of work) has alides and blocks, a from pathology of the data collection
breast cancer in relation the first year of funding eligible subjects (Task study start-up tasks, in forms, establishing a st procedures. Collection begun. Activities current review of slides by the reports into the study of tasks will continue into	on to inherited polyming, we have completed 1 of the approved standing IRB review, tudy database, and transfer in progress inceptly in progress inceptly pathologist, and database. As describe	orphisms of drug compilation of atement of work) hiring study sta aining study sta ask 2 of the app lude obtaining p nd abstracting i ed in the statem	metaboliz tumor regi . We have aff, creati aff on data proved state athology s anformation ment of wor	sing enzymes. During stry data for also completed on a collection a collection dement of work) has alides and blocks, a from pathology of the data collection
breast cancer in relation the first year of funding eligible subjects (Task study start-up tasks, in forms, establishing a st procedures. Collection begun. Activities current review of slides by the reports into the study of tasks will continue into	on to inherited polyming, we have completed 1 of the approved standing IRB review, tudy database, and transfer in progress inceptly in progress inceptly pathologist, and database. As describe	orphisms of drug compilation of atement of work) hiring study sta aining study sta ask 2 of the app lude obtaining p nd abstracting i ed in the statem	metaboliz tumor regi . We have aff, creati aff on data proved state athology s anformation ment of wor	sing enzymes. During stry data for also completed on a collection a collection dement of work) has alides and blocks, a from pathology of the data collection
breast cancer in relation the first year of fundir eligible subjects (Task study start-up tasks, in forms, establishing a start-up procedures. Collection begun. Activities currently review of slides by the reports into the study of tasks will continue into at the end of year 1.	on to inherited polyming, we have completed 1 of the approved standing IRB review, tudy database, and transfer in progress inceptly in progress inceptly pathologist, and database. As describe	orphisms of drug compilation of atement of work) hiring study sta aining study sta ask 2 of the app lude obtaining p nd abstracting i ed in the statem	metaboliz tumor regi . We have aff, creati aff on data proved state athology s anformation ment of wor	zing enzymes. During stry data for e also completed ing data collection a collection ement of work) has slides and blocks, in from pathology tk, data collection esults are available
breast cancer in relation the first year of funding eligible subjects (Task study start-up tasks, in forms, establishing a st procedures. Collection begun. Activities current review of slides by the reports into the study of tasks will continue into	on to inherited polyming, we have completed 1 of the approved structuding IRB review, tudy database, and tructudy in progress incompleted study pathologist, and database. As described years 2 and 3, so not be study pathologist.	orphisms of drug compilation of atement of work) hiring study sta aining study sta ask 2 of the app lude obtaining p nd abstracting i ed in the statem	metaboliz tumor regi . We have aff, creati aff on data proved state athology s anformation ment of wor	sing enzymes. During stry data for also completed on a collection a collection dement of work) has alides and blocks, a from pathology of the data collection

19. SECURITY CLASSIFICATION

Unclassified

OF ABSTRACT

Unclassified NSN 7540-01-280-5500

OF REPORT

17. SECURITY CLASSIFICATION

18. SECURITY CLASSIFICATION

Unclassified

OF THIS PAGE

20. LIMITATION OF ABSTRACT

Table of Contents

Cover	1
SF 298	2
Introduction	4
Body	5
Key Research Accomplishments	6
Reportable Outcomes	6
Conclusions	6
References	6
Appendices	6

INTRODUCTION

Despite the favorable prognosis for women treated for breast cancer, in some instances cancer will recur. Host factors may explain some differences in outcomes of treatment. Variability in enzyme activities could be a factor influencing sensitivity of cells to cancer treatment. Common polymorphisms occur in several genes encoding drug metabolizing enzymes, and the variant alleles affect enzyme activities. Glutathione Stransferase (GST) A1 and GSTP1 enzymes catalyze inactivating glutathionyl conjugation reactions of chemotherapeutics including cyclophosphamide. The GSTA1*B variant reduces expression of GSTA1, while a GSTP1 Val¹⁰⁵ variant reduces specific activity toward alkylating agents, so these polymorphisms may improve treatment effect by reducing removal of the drug. Data from a pilot study indicate that among women treated for breast cancer, those who are homozygous for GSTP1 Val¹⁰⁵ or GSTA1*B have improved overall survival. In the present study we will investigate whether presence of inherited variant alleles affecting activity of metabolizing enzymes affect overall survival or time to recurrence outcomes, and whether these associations are independent of other prognostic factors. The study will be a retrospective study of women (n=700) receiving first course of therapy for invasive, primary breast cancer, indentified through a hospital tumor registry. Information on vital status and recurrence will be obtained from registry follow-up data. We will determine genotypes using DNA extracted from normal tissue from archived surgical blocks. We will assess other prognostic markers in tumor tissue by immunohistochemistry. We will use survival analysis methods, taking into account other prognostic factors, to evaluate associations between genotypes and recurrence and overall survival.

BODY

This study will use archived tissue and data to examine survival of women treated for breast cancer in relation to inherited polymorphisms of drug metabolizing enzymes.

The Statement of Work identified five tasks, as follows:

- Task 1. Compilation of Data for Eligible Subjects, Months 1-3
- Task 2. Archived Tissue Specimens Obtained, Months 4-24
- Task 3. DNA Extraction and Genotyping, Months 6-30
- Task 4. Immunohistochemistry, Months 6-30
- Task 5. Data Analysis and Report Writing, Months 18-36

During the first year of funding, we have completed Task 1, compilation of tumor registry data for eligible subjects. We have also completed the following study start-up activities: IRB review and approval; hiring study staff; creating data collection forms for pathology report abstraction and pathological review of each case for eligibility; establishing a database for entering abstracted, unidentified data and tracking specimen status; training study staff on data collection procedures. Task 2, collection of tissue samples, is underway. Activities a. through f. specified under Task 2 are currently in progress including obtaining pathology slides and blocks, review of slides by the study pathologist, and abstracting information from pathology reports into the study database. Samples are being prepared to carry out laboratory assays, Tasks 3 and 4, during years 2 and 3.

KEY RESEARCH ACCOMPLISHMENTS

Data collection activities have been initiated and are proceeding. As described in the Statement of Work, data collection tasks will continue into years 2 and 3, so no reportable scientific results are available at the end of year 1. The PI presented a poster describing study methods and rationale at the "Era of Hope" Department of Defense Breast Cancer Research Program Meeting, Orlando, Florida, September 26-28, 2002.

REPORTABLE OUTCOMES

Abstract

Sweeney C, Gulbahce HE, Coles BF. Metabolizing enzyme polymorphisms and prognosis among women treated for breast cancer. "Era of Hope" Department of Defense Breast Cancer Research Program Meeting, Orlando, FL, September 26-28, 2002.

CONCLUSIONS

This study will use archived tissue and data to examine survival of women treated for breast cancer in relation to inherited polymorphisms of drug metabolizing enzymes.

Data collection activities have been initiated and are proceeding. As described in the Statement of Work, data collection tasks will continue into years 2 and 3, so no reportable scientific results are available at the end of year 1.

REFERENCES

N/A

APPENDICES

N/A